Elsevier

Journal of Nuclear Cardiology

Volume 4, Issue 6, November–December 1997, Pages 502-508
Journal of Nuclear Cardiology

Original article
Clinical relevance of radionuclide angiography and antimyosin immunoscintigraphy for risk assessment in epirubicin cardiotoxicity

https://doi.org/10.1016/S1071-3581(97)90008-8Get rights and content

Abstract

Background. Cardiotoxicity is the major limiting factor in anthracycline chemotherapy of advanced neoplastic disease. Epirubicin shows a more favorable therapeutic index than does doxorubicin, but it is still cardiotoxic. Limited data regarding epirubicin cardiotoxicity are available, and suggested guidelines for doxorubicin with left ventricular ejection fraction (LVEF) measurement may not be empirically useful for epirubicin therapy. This study evaluates the diagnostic role of antimyosin immunoscintigraphy for early identification of patients at risk for late pump dysfunction from cardiotoxicity induced by high-dose administration of epirubicin up to high cumulative dosages.

Methods and Results. Chemotherapy with epirubicin was administered to 36 patients with cancer at a dosing rate of 160 mg/m2 as a bolus injection every 21 days to a cumulative dosage of 960 mg/m2. Radionuclide angiography (LVEF) and antimyosin immunoscintigraphy with heart-lung ratio (HLR) measurements were performed before chemotherapy, at intermediate cumulative epirubicin dosages, at the end of treatment, and during the follow-up. LVEF decreased significantly at the end of the treatment and after therapy discontinuation. HLR values were significantly increased at intermediate epirubicin dosage levels and continued to increase to the end of the treatment but thereafter remained substantially unmodified for 3 to 6 months after therapy discontinuation. A value of HLR >1.85 at intermediate epirubicin dosage level showed a sensitivity of 95% and a specificity of 57% as a predictor of late LVEF impairment.

Conclusions. LVEF appears more useful at high cumulative dosages and during follow-up to monitor late pump dysfunction, whereas HLR may be effective during the early phase of the therapy in determining which patients are at risk for development of late cardiac dysfunction.

References (33)

  • RA Joss et al.

    Phase II trial of epirubicin in advanced squamous, adeno- and large cell carcinoma of the lung

    Eur J Cancer Clin Oncol

    (1981)
  • CM Young

    Epirubicin: a therapeutically active doxorubicin analogue with reduced cardiotoxicity

  • RM O'Brian et al.

    Dose response evaluation of adriamycin in human neoplasia

    Cancer

    (1977)
  • M Bastholt et al.

    Epirubicin at four different dose levels in metastatic breast cancer: a randomized trial

  • RB Jones et al.

    A phase I-II study of intensive dose adriamycin for advanced breast cancer

    J Clin Oncol

    (1987)
  • HM Pinedo et al.

    Cyvadic in advanced soft tissue sarcoma: a randomized study comparing two schedules

  • Cited by (26)

    • Transduction catalysis: Doxorubicin amplifies rAAV-mediated gene expression in the cortex of higher-order vertebrates

      2021, iScience
      Citation Excerpt :

      As a chemotherapeutic drug, doxorubicin takes effect in cancer treatment by inhibiting cell proliferation and inducing apoptosis (Tacar et al., 2013). For non-dividing cells, such as neurons, there is less expectation of significant cytotoxicity (although cardiac tissues are known to be affected in high-dose schedules) (Maini et al., 1997). Direct delivery into the brain, rather than intravenous administration, restricts doxorubicin uptake to cells within the local injection area.

    • Nuclear Medicine Imaging and Cardiotoxicity

      2017, Anticancer Treatments and Cardiotoxicity: Mechanisms, Diagnostic and Therapeutic Interventions
    • Noninvasive imaging of cardiovascular injury related to the treatment of cancer

      2014, JACC: Cardiovascular Imaging
      Citation Excerpt :

      Investigators developed monoclonal antibodies, 111In and 99mTc, to identify these heavy chains and thereby assess the degree of myocyte damage in response to inflammation. Studies by Valdes Olmos et al. (101) and Maini et al. (102) both show positive correlation between the cumulative dose of anthracycline and the uptake of antimyosin in the myocardium, with later deterioration of LVEF (101,102) (Fig. 3). Importantly, however, the specificity of 111In-antimyosin scintigraphy is low (25% to 50%) for predicting decrements in LVEF 12 months after receipt of cancer treatment (78).

    View all citing articles on Scopus
    View full text